神经内分泌肿瘤的个体化177Lu-奥曲肽肽受体放射性核素治疗:一项模拟研究
该模拟研究基于36例接受122个固定注射放射性活度177Lu-奥曲肽肽受体放射性核素治疗周期的神经内分泌肿瘤患者数据,设计基于剂量学的个体化方案,并在22例完成四周期诱导治疗的 retrospective 队列中模拟。结果显示个体化方案可将累积注射放射性活度增至43.7±16.5 GBq,肾脏、骨髓和最大肿瘤累积吸收剂量分别达21.5±2.5、1.63±0.61和163.4±85.9 Gy,肿瘤累积最大吸收剂量较经验性方案平均增加1.48倍(范围0.68-2.64倍;P=0.0013)。
要点
- 个体化方案通过调整每周期注射活度使四周期肾脏吸收剂量达23 Gy,模拟累积注射活度为43.7±16.5 GBq。
- 模拟个体化方案下肿瘤最大累积吸收剂量为163.4±85.9 Gy,较经验性方案平均增加1.48倍(P=0.0013)。
- 该模拟提示个体化方案有潜力在限制毒性的同时增加肿瘤吸收剂量。
核心结论
- 通过标准化诱导疗程中肾脏吸收剂量,个体化肽受体放射性核素治疗有潜力显著增加肿瘤吸收剂量,从而在限制毒性的同时增强治疗获益。
研究设计与样本
- 模拟研究,基于36例接受122个固定注射放射性活度177Lu-奥曲肽肽受体放射性核素治疗周期并有定量SPECT/CT剂量学的神经内分泌肿瘤患者。
- 其中22例完成四周期诱导疗程,累积注射放射性活度为29.6±2.4 GBq。
主要发现
- 经验性固定活度方案下,肾脏、骨髓和最大肿瘤吸收剂量分别为16.2±5.5、1.3±0.8和114±66 Gy。
- 模拟个体化方案下,四周期累积注射放射性活度可增至43.7±16.5 GBq(每周期10.9±5.0 GBq)。
- 模拟个体化方案下,累积肾脏、骨髓和最大肿瘤吸收剂量分别为21.5±2.5、1.63±0.61和163.4±85.9 Gy。
- 模拟个体化方案较经验性方案,累积最大肿瘤吸收剂量平均增加1.48倍(范围0.68-2.64倍;P=0.0013)。
关键数值与推荐
- 个体化方案中,第一周期每注射活度的肾脏吸收剂量由体表面积和肾小球滤过率预测,后续周期由前一周期肾脏剂量学预测。
- 每周期调整个体化注射活度,以使四周期肾脏吸收剂量达到处方值23 Gy。
- 当肾脏或骨髓功能受损时,个体化注射活度减少25-50%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Peptide receptor radionuclide therapy (PRRT) with 177Lu-octreotate is commonly administered at empiric, fixed amounts of injected radioactivity (IA). This results in highly variable absorbed doses to critical organs and suboptimal treatment of most patients. The primary aims of this study were to design a personalized PRRT (P-PRRT) protocol based on dosimetry, and to perform a simulation of this protocol in a retrospective cohort of patients with neuroendocrine tumours, in order to assess the potential of P-PRRT to safely increase the absorbed dose to the tumour during a four-cycle induction course. METHODS: Thirty-six patients underwent 122 fixed-IA 177Lu-octreotate PRRT cycles with quantitative SPECT/CT-based dosimetry. Twenty-two patients completed a four-cycle induction course (29.6 ± 2.4 GBq cumulative IA), with kidney, bone marrow and maximum tumour absorbed doses of 16.2 ± 5.5, 1.3 ± 0.8, and 114 ± 66 Gy, respectively. We simulated a P-PRRT regime in which the renal absorbed dose per IA was predicted by the body surface area and glomerular filtration rate for the first cycle, and by renal dosimetry of the previous cycle(s) for the following cycles. Personalized IA was adjusted at each cycle in order to reach the prescribed renal absorbed dose of 23 Gy over four cycles (with a 25-50% reduction when renal or bone marrow function was impaired). Simulated IA and absorbed doses were based on actual patient characteristics, laboratory values and absorbed doses per IA delivered at each cycle. RESULTS: In the P-PRRT regime, cumulative IA could have been increased to 43.7 ± 16.5 GBq over four induction cycles (10.9 ± 5.0 GBq per cycle), yielding cumulative kidney, bone marrow and maximum tumour absorbed doses of 21.5 ± 2.5, 1.63 ± 0.61, and 163.4 ± 85.9 Gy, respectively. This resulted in an average 1.48-fold increase in cumulative maximum tumour absorbed dose over empiric PRRT (range, 0.68-2.64-fold; P = 0.0013). CONCLUSION: By standardizing the renal absorbed dose delivered during the induction course, P-PRRT has the potential to significantly increase tumour absorbed dose, thus to augment the therapeutic benefit while limiting toxicity.
引用
- Del Prete M, Buteau FA, Beauregard JM, et al. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study. Eur J Nucl Med Mol Imaging. 2017. PMID: 28361189. doi:10.1007/s00259-017-3688-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。